Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
|Videos|February 22, 2020
Dr. Dandoy on Overcoming Challenges with TA-TMA
Author(s)Christopher E. Dandoy, MD, MSc
Christopher E. Dandoy, MD, MSc, shares advice for how to overcome the challenges in managing transplanted-associated thrombotic microangiopathy. The primary challenges are diagnosing and identifying TA-TMA in patients.
Advertisement
Christopher E. Dandoy, MD, MSc, a professor at Cincinnati Children’s Hospital, shares advice for how to overcome the challenges in managing transplanted-associated thrombotic microangiopathy (TA-TMA). The primary challenges are diagnosing and identifying TA-TMA in patients.
Dandoy recommends screening for TA-TMA to overcome this issue. Institutions should obtain complete blood counts for the first month in patients following transplant, as well as renal profiles to look at kidney injury on a daily basis. In addition, physicians should look at lactate dehydrogenase, urine, and for signs of schistocytes in the blood. Dandoy concludes they should also monitor blood pressure closely.
Advertisement
Related to this article
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
3
NMPA Accepts Toripalimab Plus Chemotherapy Application for Expanded Stage II-III NSCLC Use
4
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
5